Emcure Pharmaceuticals Limited (EMCURE) Price & Analysis

Compare

2 Followers

EMCURE Stock Chart & Stats

₹1345.35

₹31.90(2.25%)

At close: Jan 08 4:00 PM EST

₹1345.35

₹31.90(2.25%)

Day’s Range― - ―

52-Week Range₹890.00 - ₹1,567.80

Previous CloseN/A

Volume1.63K

Average Volume (3M)197.42K

Market Cap

₹291.96B

Enterprise Value₹255.38B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)36.8

Beta1.12

Next Earnings

Feb 05, 2026

EPS Estimate

10.8

Next Dividend Ex-DateN/A

Dividend Yield0.21%

Share Statistics

EPS (TTM)12.80

Shares Outstanding189,572,540

10 Day Avg. Volume24,274

30 Day Avg. Volume197,417

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,670.00

Price Target Upside24.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Emcure Pharmaceuticals Limited News

Lilly vs. Novo Nordisk: Who Will Lead India’s Growing Obesity-Drug Market?

U.S.-based Eli Lilly & Co. ($LLY) and Danish drug maker Novo Nordisk ($NVO) are vying to capture a...

18d ago

LLY

NVO

Emcure Pharmaceuticals Confirms SEBI Dematerialisation Compliance for December Quarter

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) just unveiled an update. Emcure Pharmaceuticals has informed the stock exchanges that...

5d ago

Emcure Pharmaceuticals Closes Trading Window Ahead of Q3 FY2026 Results

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has announced the closure...

17d ago

Emcure Pharmaceuticals Allots 7,700 Shares Under Employee Stock Option Scheme

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has issued an announcement. Emcure Pharmaceuticals Limited has announced the allotment of...

26d ago

Emcure Pharmaceuticals Schedules Investor Conference Meeting

An update from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) is now available. Emcure Pharmaceuticals Limited has announced its...

1M ago

Emcure Pharmaceuticals Schedules Virtual AGM with E-Voting

The latest announcement is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals Limited announced the scheduling...

5M ago

EMCURE FAQ

What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹890.00 and its highest was ₹1567.80 in the past 12 months.

What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹291.96B.

When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

Emcure Pharmaceuticals Limited’s upcoming earnings report date is Feb 05, 2026 which is in 25 days.

How were Emcure Pharmaceuticals Limited’s earnings last quarter?

Emcure Pharmaceuticals Limited released its earnings results on Nov 11, 2025. The company reported ₹12.8 earnings per share for the quarter, beating the consensus estimate of ₹12 by ₹0.8.

Is Emcure Pharmaceuticals Limited overvalued?

According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.21%. See more information on Emcure Pharmaceuticals Limited dividends here

What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate is 10.8.

How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,572,540 shares outstanding.

What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?

Emcure Pharmaceuticals Limited reported an EPS of ₹12.8 in its last earnings report, beating expectations of ₹12. Following the earnings report the stock price went down -4.224%.

Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Emcure Pharmaceuticals Limited (EMCURE) Earnings & Revenues

Historic Earnings Reports

EMCURE Stock 12 Month Forecast

Average Price Target

₹1,670.00

▲(24.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1018":"₹1,018","1711":"₹1,711","1191.25":"₹1,191.3","1364.5":"₹1,364.5","1537.75":"₹1,537.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.71K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1670,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.67K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1630,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.63K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1018,1191.25,1364.5,1537.75,1711],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1318,1348.1538461538462,1378.3076923076924,1408.4615384615386,1438.6153846153845,1468.7692307692307,1498.923076923077,1529.076923076923,1559.2307692307693,1589.3846153846152,1619.5384615384614,1649.6923076923076,1679.8461538461538,{"y":1710,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1318,1345.076923076923,1372.1538461538462,1399.2307692307693,1426.3076923076924,1453.3846153846155,1480.4615384615386,1507.5384615384614,1534.6153846153845,1561.6923076923076,1588.7692307692307,1615.8461538461538,1642.923076923077,{"y":1670,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1318,1342,1366,1390,1414,1438,1462,1486,1510,1534,1558,1582,1606,{"y":1630,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1359.39,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1316.18,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1387.18,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1490.67,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1441.72,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1387.03,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1387.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1458.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1226.51,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1019.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1361.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1378.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1318,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >